NCT07300085
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 4 → 15 locations
- Notable Enrollment reopened
- Study sites: 4 to 2
- Notable Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 3 of 4 entries
Notable Enrollment increased: 100 → 710 participantsv3 Show 8 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria shortened, about 1,424 words
- Study sites: 2 to 4
- Primary and study completion dates: Dec 2026 to Dec 31, 2026
- Interventions: CD388 Injection (Combination Product), Fluzone HD influenza vaccine (Biological), Placebo (Combination Product) to Fluzone® High-Dose (HD) influenza vaccine (Biological), MK-1406 Injection (Combination Product), Placebo (Combination Product)
- Secondary endpoints: 1 to 4
- Study description shortened, about 17 words
- Study title expanded, about 1 word
- Notable Sponsor changed: Cidara Therapeutics Inc. to Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Primary and study completion dates: May 2026 to Dec 2026
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Geometric Mean of Hemagglutinin Inhibition (HAI) Titers Against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® High-Dose (HD) and MK-1406 Compared to Participants Who Receive Fluzone® HD and Placebo
Timeframe: Predose (Day 1), Day 15 and Day 29
Percentage of Participants with Seroconversion Rates against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® HD and MK-1406 Compared to Participants Who Receive Fluzone® HD and Placebo
Timeframe: Predose (Day 1), Day 15 and Day 29
Secondary (4)
Percentage of participants with ≥1 Adverse Event (AE)
Percentage of Participants Who Discontinued from the Study Due to an Adverse Event
Percentage of Participants with a Solicited Injection-site Adverse Event
Percentage of Participants with a Solicited Systemic Adverse Event
Arms and interventions
Fluzone® High-Dose (HD) plus MK-1406Experimental
Participants will receive open-label Fluzone® HD influenza vaccine by intramuscular (IM) injection plus MK-1406 by subcutaneous (SC) injection on Day 1.
Fluzone® HD plus PlaceboPlacebo comparator
Participants will receive open-label Fluzone® HD influenza vaccine by IM injection plus placebo by SC injection on Day 1.
Biologicals: Fluzone® High-Dose (HD) influenza vaccine
Combination products: MK-1406 Injection, Placebo
Sites
15 sites in 1 country